Advances in anticancer antibody-drug conjugates and immunotoxins

Recent Patents on Anti-Cancer Drug Discovery

Volumn 9, Issue 1, 2014, Pages 35-65

  Dosio, Franco ^a   Stella, Barbara ^a   Cerioni, Sofia ^a   Gastaldi, Daniela ^a   Arpicco, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antibody drug conjugate; Anticancer agents; Auristatins immunotoxin; Calicheamicins; Cross linkers; Duocarmycins; Maytansinoids

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; B CELL ACTIVATING FACTOR; BL 22; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CD19 ANTIBODY; CINTREDEKIN BESUDOTOX; COMBOTOX; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; ERB 38; GELONIN; GLEMBATUMUMAB VEDOTIN; HLL1 DOX; HUM 195 RGEL IMMUNOTOXIN; HYBRID PROTEIN; IMMU 30; IMMUNOTOXIN; IMMUNOTOXIN LMB2; IMTOX 25; MOXETUMOMAB PASUDOTOX; MR 1 1; NAPTUMOMAB ESTAFENATOX; NK 408; OPORTUZUMAB MONATOX; PENTOSTATIN; PODOPLANIN; PSEUDOMONAS EXOTOXIN; RICIN; TP 38; UCHT 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER CELL; CLINICAL TRIAL (TOPIC); COLON CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MESOTHELIOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTOXINS; NEOPLASMS; PATENTS AS TOPIC;

EID: 84901272392     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/15748928113089990045     Document Type: Article

References (330)

1. Reichert JM. Which are the antibodies to watch in 2012? mAbs 2012; 4(1): 1-3.
2. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012; 17(17-18): 954-63.
3. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 2011; 286(6): 4165-72.
4. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components. Toxins 2011; 3(7): 848-83.
5. Litvak-Greenfeld D, Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv Drug Deliv Rev 2012; 64(15): 1782-99.
6. Lorberboum-Galski H. Human toxin-based recombinant immunotoxins/ chimeric proteins as a drug delivery system for targeted treatment of human diseases. Exp Opin Drug Deliv 2011; 8(5): 605-21.
7. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58: 221-37.
8. Chaddock JA, Acharya KR. Engineering toxins for 21st century therapies. FEBS J 2011; 278(6): 899-904.
9. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011; 16(11): 495-503.
10. Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 2012; 15(3): 300-9.
11. Wolf P, Elsasser-Beile U. Pseudomonas exotoxin A: From virulence factor to anti-cancer agent. Int J Med Microbiol 2009; 299(3): 161-76.
12. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27(18): 2983-90.
13. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and Phase I clinical trial. Clin Cancer Res 2010; 16(6): 1894-903.
14. Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox J, et al. CAT-8015: A second-generation Pseudomonas exotoxin abased immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res 2009; 15(3): 832-9.
15. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002; 8(4): 995-1002.
16. Pastan, I.H., Salvatore, G., Beers, R., Kreitman, R.J. Mutated anti- CD22 antibodies with increased affinity to CD22-expressing leukemia cells. WO2003027135 (2003).
17. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30(15): 1822-8.
18. Kreitman RJ, Arons E, Sapolsky J, Roth L, Zhou H, Wilson WH, et al. Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR). J Clin Oncol 2012; 30: Abs 2503.
19. Wayne, A.S., Pastan, I., Kaucic, K., Lechleider, R. Methods of treating pediatric acute lymphoblastic leukemia with an anti-CD22 immunotoxin. US20120177567 (2012).
20. Pastan, I.H, Ho, M., Bang, S.-H. Mutated anti-CD22 antibodies and immunoconjugates. WO2005052006 (2005).
21. Pastan, I.H., Onda, M., Nagata, S., Fitzgerald, D., Kreitman, R., Lee, B. Mutated Pseudomonas exotoxins with reduced antigenicity. WO2007016150 (2007).
22. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, Fitzgerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113(16): 3792-800.
23. Pastan, I.H, Weldon, J., Fitzgerald, D. Deletions in domain II of pseudomonas exotoxin a that reduce non-specific toxicity. WO2009032954 (2009).
24. Pastan, I.H., Beers, R., Onda, M. Improved Pseudomonas exotoxin A with reduced immunogenicity. WO2011032022 (2011).
25. Liu WH, Onda M, Kim C, Xiang LM, Weldon JE, Lee B, et al. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Eng Des Sel 2012; 25(1): 1-6.
26. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Nat Acad Sci USA 2012; 109(29): 11782-7.
27. Harding, F.A. Pseudomonas exotoxin CD4+ T-cell epitopes. WO2007031741 (2007).
28. Pastan IH, Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Kreitman RJ, Vasmatzis, G., Lee, B. Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point. WO02040545 (2002).
29. Digan, M.E., Lake, P., Wright, R.M. Anti-CD3 immunotoxins and therapeutic uses therefor. WO00041474 (2000).
30. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18(8): 1622-36.
31. Singh R, Zhang Y, Pastan I, Kreitman RJ. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin Cancer Res 2012; 18(1): 152-60.
32. Weldon JE, Pastan I. A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011; 278(23): 4683-700.
33. Traini R, Kreitman RJ. Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin. Bioconjug Chem 2011; 22(4): 736-40.
34. Fey, G.H., Schwemmlein, M. CD33-specific single-chain immunotoxin and method of use. WO2007014743 (2007).
35. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13(1): 47-58.
36. Fey, G.H., Peipp, M., Schwemmlein, M. CD19-specific immunotoxin and treatment method. WO2007085470 (2007).
37. Waurzyniak B, Schneider EA, Tumer N, Yanishevski Y, Gunther R, Chelstrom LM, et al. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 1997; 3(6): 881-90.
38. Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of patients with T-Cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma 1997; 26(3-4): 287-98.
39. Flavell DJ, Warnes S, Noss A, Flavell SU. Host-mediated antibody- dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia. Cancer Res 1998; 58(24): 5787-94.
40. Uckun, F.M. Method for treating T-lineage leukemias and lymphomas using a CD7-specific monoclonal antibody (TXU-7) linked to the pokeweed antiviral protein (PAP). US6689362 (2004).
41. Peipp M, Kupers H, Saul D, Schlierf B, Greil J, Zunino SJ, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 2002; 62(10): 2848-55.
42. Fey, G.H.M., Gramatzki, M., Peipp, M. Anti-CD7 immunotoxin as fusion protein. WO03051926 (2003).
43. Gattenlohner S, Jorissen H, Huhn M, Vincent A, Beeson D, Tzartos S, et al. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J Biomed Biotechnol 2010; 2010: 187621. doi: 10.1155/2010/187621.
44. Vincent, A., Marx, A., Gattenlohner, S. Immunotoxin derived from a recombinant human autoantibody and method of using thereof. US20060013809 (2006).
45. Zhao, Y., Ma, J., Chen, Z., Jiao, Y., Cui, B. Recombinant human PE38sBAFF immunotoxin and coding gene and use thereof. CN102206283 (2011).
46. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44(1): 46-53.
47. Kreitman RJ, Hassan R, FitzGerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15(16): 5274-9.
48. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13(17): 5144-9.
49. Pak Y, Zhang YJ, Pastan I, Lee B. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res 2012; 72(13): 3143-52.
50. Du X, Xiang L, Mackall C, Pastan I. Killing of resistant cancer cells with low bak by a combination of an antimesothelin immunotoxin and a TRAIL receptor 2 agonist antibody. Clin Cancer Res 2011; 17(18): 5926-34.
51. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the ErbB2 receptor. Clin Cancer Res 1999; 5(9): 2311-5.
52. von Minckwitz G, Harder S, Hovelmann S, Jager E, Al-Batran SE, Loibl S, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005; 7(5): R617-26.
53. MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, et al. A Phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther 2008; 2: 105-14.
54. Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, et al. A Phase i study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscleinvasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des Devel Ther 2010; 4: 313-20.
55. Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, et al. A Phase II study of oportuzumab monatox: An immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guarin. J Urol 2012; 188(5): 1712-8.
56. Fitzgerald, D.J., Sarnovsky, R. Immunotoxins and uses thereof. WO2009149281 (2009).
57. Benhar, I., Mazor, Y. Recombinant fusion protein and polynucleotide construct for immunotoxin production. US20080292646 (2008).
58. Barnea, I., Benhar, I., Ben-Yosef, R., Vexler, A. Recombinant fusion protein and polynucleotide construct for immunotoxin production. US20120076780 (2012).
59. Shapira A, Benhar I. Toxin-based therapeutic approaches. Toxins 2010; 2(11): 2519-83.
60. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody- toxin specific for the erbB-2 receptor. Cancer Res 1992; 52(22): 6310-7.
61. Wels, W.S., Daelken, B., Schwarz, S.E. Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins. WO2009010228 (2009).
62. Wang X, Zhao Y, Xuchen C. Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast J 2010; 16(1): 32-7.
63. Niu, R., Zhang, L., Wang, D., Shi, Y., Wei, X., Yang, Y., Huang, J., Niu, Y., Sun, B., Hao, X. Human breast cancer resisting recombination immunotoxin M4G3/ScFv-PE40. CN101148475 (2008).
64. Forsberg G, Skartved NJ, Wallen-Ohman M, Nyhlen HC, Behm K, Hedlund G, et al. Naptumomab estafenatox, an engineered antibody- superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother 2010; 33(5): 492-9.
65. Bigner, D., Kuan, C.-T., Pastan, I.H., Pegram, C.N. Dual specific immunotoxin for brain tumor therapy. US20090269343 (2009).
66. Bigner, D., Kuan, C.-T., Pastan, I.H., Chandramohan, V. Antipodoplanin antibodies and methods of use. WO2012075490 (2012).
67. Huber GF, Fritzsche FR, Zullig L, Storz M, Graf N, Haerle SK, et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer 2011; 129(6): 1404-9.
68. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, et al. Phase III randomized trial of CED of IL13- PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro- Oncol 2010; 12(8): 871-81.
69. Sampson JH, Archer G, Pedain C, Wembacher-Schroder E, Westphal M, Kunwar S, et al. Poor drug distribution as a possible ex planation for the results of the PRECISE trial. J Neurosurg 2010; 113(2): 301-9.
70. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008; 10(3): 320-9.
71. Vallera, D.A. Receptor-targeting reagents. WO2009029601 (2009).
72. Hu, J., Yang, H., Li, J., Wei, Y., Guo, K. Fusion protein containing guide peptide and GnRH-PE39KDEL as well as nucleic acid and application thereof. CN102603897 (2012).
73. Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978; 15(1): 245-50.
74. Greenfield L, Johnson VG, Youle RJ. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987; 238(4826): 536-9.
75. Williams DP, Snider CE, Strom TB, Murphy JR. Structure-function analysis of interleukin-2-toxin (DAB486-IL-2) - fragment-b sequences required for the delivery of fragment-a to the cytosol of target-cells. J Biol Chem 1990; 265(20): 11885-9.
76. Chaudhary VK, Fitzgerald DJ, Pastan I. A proper amino terminus of diphtheria-toxin is important for cytotoxicity Biochem Biophys Res Commun 1991; 180(2): 545-51.
77. Potala S, Sahoo SK, Verma RS. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discov Today 2008; 13(17-18): 807-15.
78. Neville, D.M., Jr., Thompson, J.T., Hu, H., Woo, J.-H., Ma, S., Hexham, J.M., Digan, M.E. Immunotoxin fusion proteins and means for expression thereof. WO01087982 (2001) & US7696338 (2010).
79. Manoukian G, Hagemeister F. Denileukin diftitox: A novel immunotoxin. Expert Opin Biol Ther 2009; 9(11): 1445-51.
80. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007; 136(3): 439-47.
81. Talpur R, Duvic M. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral t-cell lymphomas. Clin Lymphoma Myeloma Leuk 2012; 12(3): 180-5.
82. Yamada Y, Aoyama A, Tocco G, Boskovic S, Nadazdin O, Alessandrini A, et al. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates. J Immunol 2012; 188(12): 6063-70.
83. Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, et al. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer 2011; 11.
84. Potala S, Verma RS. Modified DT-IL2 fusion toxin targeting uniquely IL2R alpha expressing leukemia cell lines - Construction and characterization. J Biotechnol 2010; 148(2-3): 147-55.
85. Woo JH, Bour SH, Dang T, Lee YJ, Park SK, Andreas E, et al. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390- bisFv(UCHT1). Cancer Immunol Immunother 2008; 57(8): 1225-39.
86. Neville, D., Woo, J.-H., Frankel, A. A fold-back diabody diphtheria toxin immunotoxin and methods of use. WO2009017823 (2009).
87. Frankel, A.E. Methods and compositions based on diphtheria toxininterleukin- 3 conjugates. US2009232767 (2009).
88. Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leukemia Res 2009; 33(9): 1233-42.
89. Vallera, D., Lion, J. Methods and compositions for bi-specific targeting of CD19/CD22. WO2010107658 (2010).
90. Zhang, Z., Chai, Y., Yao, L., Chen, A. Recombinant vascular endothelial growth factor-diphtherin fusion protein, its preparation and application. CN1477129 (2004).
91. Zhang, L., Chen, W., Li, H., Jia, Y., Li, M. Plasmid of recombinant immunotoxin IP 10-DT 390 aimed at activating Th1 cell, and its preparing method and use. CN1641035A (2005).
92. Chen W, Li H, Jia Y, Lv M, Li M, Feng P, et al. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390- IP-10 attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2007; 28(1): 30-40.
93. Jia Y, Li H, Chen W, Li M, Lv M, Feng P, et al. Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. Gene Ther 2006; 13(18): 1351-9.
94. Zhang, L., Jia, Y., Li, H., Chen, W., Li, M. Plasmid of recombinant immunotoxin Rantes-DT390 aimed at activating Th1 cell, and its preparing method and use. CN1641023 (2005).
95. Zhang, L.L. Plasmid containing recombinant immunological toxin MIP-1-DT390 aiming at activated Th1 cell, its preparation method and uses. CN1766114 (2006).
96. Lu ML, Li H, Liang WB, Chen WJ, Jia Y, Jiang ZH, et al. The research on construction and expression of eukaryotic expression plasmid for a recombinant immunotoxin mMIP-1alpha-DT390. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38(1): 1-5.
97. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) therapy of malignant gliomas. J Neurooncol 2003; 65(1): 3-13.
98. Yoon DJ, Chu DSH, Ng CW, Pham EA, Mason AB, Hudson DM, et al. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J Control Release 2009; 133(3): 178-84.
99. Kamei, D.T., Lao, B.J., Tsai, W.-L.P., Mashayekhi, F., Pham, E.A., Mason, A.B. Improved cancer drug delivery using modified transferrin. WO2009149393 (2009).
100. Stish BJ, Oh S, Vallera DA. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J NeuroOncol 2008; 87(1): 51-61.
101. Huang J, Li YM, Massague J, Sicheneder A, Vallera DA, Hall WA. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer. J Neuro Oncol 2012; 109(2): 229-38.
102. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells: What each is teaching us about the others. Am J Pathol 1993; 142(4): 965-74.
103. Potala S, Verma RS. Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1. Mol Biol Rep 2011; 38(2): 1389-97.
104. Davis, C.G., Datta, D. Modified diphtheria toxins. WO2008157776 (2008).
105. Blakey DC, Watson GJ, Knowles PP, Thorpe PE. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res 1987; 47(4): 947-52.
106. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule - a new cytokine receptor of the tumornecrosis- factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85(1): 1-14.
107. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003; 14(5): 729-36.
108. Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000; 14(5): 853-8.
109. Vitetta, E.S., Liu, X.-Y., Pop, L. Recombinant anti-CD19 monoclonal antibodies. WO2012057765 (2012).
110. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, et al. A Phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009; 31(12): 936-41.
111. Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I, et al. A Phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011; 154(4): 471-6.
112. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. Bio Drugs 2009; 23(1): 1-13.
113. Smallshaw JE, Ghetie V, Rizo J, Fulmer JR, Trahan LL, Ghetie MA, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nature Biotechnol 2003; 21(4): 387-91.
114. Liu XY, Pop LM, Schindler J, Vitetta ES. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity. mAbs 2012; 4(1): 57-68.
115. Battelli MG. Cytotoxicity and toxicity to animals and humans of ribosome-inactivating proteins. Mini Rev Med Chem 2004; 4(5): 513-21.
116. Better, M.D., Carroll, S.F. Proteins encoding gelonin sequences. US6146850 (2000).
117. Rosenblum, M.G., Mehta, K. Potentiation of anti-CD38- immunotoxin cytotoxicity. WO00040265 (2000).
118. Rosenblum, M.G. Immunotoxin as a therapeutic agent and uses thereof. WO03105761 (2003).
119. Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V. The growth factor fusion construct containing Blymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 2007; 109(6): 2557-64.
120. Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, et al. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia 2012; 26(8): 1786-96.
121. Luster TA, Mukherjee I, Carrell JA, Cho YH, Gill J, Kelly L, et al. Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo. PLoS ONE 2012; 7(10): e47361
122. Pagliaro LC, Liu BS, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, et al. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: An anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res 1998; 4(8): 1971-6.
123. Dean A, Talpaz M, Kantarjian H, Faderl S, Jabbour E, Ravandi, KF, et al. Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients with advanced myeloid malignancies. J Clin Oncol 2010; 28: 6549.
124. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, et al. In vitro and in vivo studies of a VEGF 121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 2002; 99(12): 7866-71.
125. Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, et al. Cytotoxicity of VEGF 121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer 2011; 11: Article No. 358.
126. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, et al. Inhibition of prostate cancer osteoblastic progression with VEGF 121/rGEL, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res 2011; 17(8): 2328-38.
127. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, et al. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 2005; 7(10): 912-20.
128. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, et al. Single-chain antibody-based immunotoxins targeting her2/neu: Design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2012; 11(1): 143-53.
129. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 1999; 5(4): 865-74.
130. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: In vitro and in vivo studies. Cancer Res 2009; 69(23): 8987-95.
131. Pirie, C.M., Liu, D.V., Yang, N., Wittrup, K.D. Compositions and methods for macromolecular drug delivery. WO2012094653 (2012).
132. Wittrup, K.D., Spangler, J.B., Hackel, B.J. Engineered proteins including mutant fibronectin domains. WO2011020033 (2011).
133. Zhou X, Qiu J, Wang Z, Huang N, Li X, Li Q, et al. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. J Cancer Res Clin Oncol 2012; 138(7): 1081-90.
134. Li, J., Wei, Y. Anti-EGFR single-chain antibody fusion Gelonin recombination immunotoxin, preparation method and usage thereof. CN101671397 (2010).
135. Cizeau, J., MacDonald, G. Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers. WO2008052322 (2008).
136. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC. Engineering and biological characterization of VB6-845, an Anti- EpCAM immunotoxin containing a t-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 2009; 32(6): 574-84.
137. Bolognesi A, Polito L, Olivieri F, Valbonesi P, Barbieri L, Battelli MG, et al. New ribosome-inactivating proteins with polynucleotide: Adenosine glycosidase and antiviral activities from Basella rubra L. and Bougainvillea spectabilis Willd. Planta 1997; 203(4): 422-9.
138. Kowalski M, Brazas L, Zaretsky R, Rasamoelisolo M, MacDonald G, Cuthbert W, et al. A Phase I study of VB6-845, an anti-EpCAM fusion protein targeting advanced solid tumours of epithelial origin: Preliminary results. J Clin Oncol 2008; 26(suppl): 14663.
139. Rybak SM, Arndt MAE, Schirrmann T, Dübel S, Krauss J. Ribonucleases and immunoRNAses as anticancer drugs. Curr Pharm Des 2009; 15(23): 2665-75.
140. Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, et al. Human angiogenin fused to human CD30 ligand (Ang- CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001; 61(24): 8737-42.
141. Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase. Cancer Invest 2005; 23(7): 643-50.
142. Lee I. Ranpirnase (Onconase®), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther 2008; 8(6): 813-27.
143. Jakobsen JN, Sorensen JB. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol 2011; 68(1): 1-15.
144. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma. Blood 2001; 97(2): 528-35.
145. Chang CH, Sapra P, Vanama SS, Hansen HJ, Horak ID, Goldenberg DM. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005; 106(13): 4308-14.
146. Goldenberg, D.M., Hansen, H.J., Chang, C.-H., Vanama, S., Rossi, E.A. Fusion proteins containing recombinant cytotoxic RNAses. WO2005080586 (2005).
147. Chang CH, Gupta P, Michel R, Loo M, Wang Y, Cardillo TM, et al. Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells. Mol Cancer Ther 2010; 9(8): 2276-86.
148. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, et al. TROP2: A novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21(2): 186-91.
149. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12(10): 3057-63.
150. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. British J Cancer 2008; 99(8): 1290-5.
151. Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res 2011; 30: Article No. 106.
152. Chang, C.-H., Goldenberg, D.M., Rossi, E.A. Compositions and methods of use of immunotoxins comprising ranpirnase (RAP) show potent cytotoxic activity. WO2011026026 (2011).
153. Rossi EA, Chan E, Gupta P, Goldenberg DM, Chang CH. A novel ribonuclease-based immunotoxin comprising quadruple ranpirnase (RAP) site-specifically conjugated to an anti-CD22 IgG showing potent anti-lymphoma activity. 51st ASH Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA, USA.
154. Chang, C.-H., Goldenberg, D.M. Dock-and-lock (DNL) complexes for delivery of interference RNA. US2011123436 (2011).
155. Chang, C.-H., Goldenberg, D.M. Dock-and-lock (DNL) vaccines for cancer therapy. US7901680 (2011).
156. Chang, C.-H., Goldenberg, D.M. Bispecific immunocytokine dockand- lock (DNL) complexes and therapeutic use thereof. US20110020273 (2011).
157. Chang, C.-H., Goldenberg, D.M. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy. US20120082685 (2012).
158. Chang, C.-H., Goldenberg, D.M. Stem cell targeting with dockand- lock (DNL) complexes. US20120093769 (2012).
159. Rossi EA, Goldenberg DM, Chang CH. Complex and defined biostructures with the dock-and-lock method. Trends Pharmacol Sci 2012; 33(9): 474-81.
160. Rufini A, Melino G. Cell death pathology: The war against cancer. Biochem Biophys Res Commun 2011; 414(3): 445-50.
161. Wang F, Ren J, Qiu XC, Wang LF, Zhu Q, Zhang YQ, et al. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin Cancer Res 2010; 16(8): 2284-94.
162. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5(11): 897-907.
163. Zhang DX, Zhao PT, Xia L, Liu LL, Liang J, Zhai HH, et al. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein. Gut 2010; 59(3): 292-9.
164. Wang LF, Zhou Y, Xu YM, Qiu XC, Zhou BG, Wang F, et al. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. Cancer Invest 2009; 27(7): 774-80.
165. Kurschus FC, Jenne DE. Delivery and therapeutic potential of human granzyme B. Immunol Rev 2010; 235(1): 159-71.
166. Rosenblum, M.G., Liu, Y. Therapeutic agents comprising proapoptotic proteins. WO03007889 (2003).
167. Rosenblum, M., Cheung, L. Modified proteins, designer toxins, and methods of making thereof. US8138311 (2012).
168. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Cell Biol 2010; 14(4): 529-37.
169. Ulbrich, K., Etrych, T., Rihova, B., Jelinkova, M., Kovar, M. pHsensitive polymeric conjugates of an anthracycline drug. WO03053473 (2003).
170. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 2008; 15(18): 1802-26.
171. Damen EWP, Nevalainen TJ, van den Bergh TJM, de Groot FMH, Scheeren HW. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg Med Chem 2002; 10(1): 71-7.
172. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011; 71(20): 6300-9.
173. Lee MD, Manning JK, Williams DR, Kuck NA, Testa RT, Borders DB. Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J Antibiot (Tokyo) 1989; 42(7): 1070-87.
174. Lee MD, Dunne TS, Siegel MM, Chang CC, Morton GO, Borders DB. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin. gamma.1I. J Am Chem Soc 1987; 109(11): 3464-6.
175. Lee MD, Dunne TS, Chang CC, Ellestad GA, Siegel MM, Morton GO, et al. Calichemicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calichemicin. gamma.1I. J Am Chem Soc 1987; 109(11): 3466-8.
176. Smith AL, Nicolaou KC. The enediyne antibiotics. J Clin Cancer Res 1996; 39(11): 2103-17.
177. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17(20): 6417-27.
178. Sievers EL, Linenberger M. Mylotarg: Antibody-targeted chemotherapy comes of age. Curr Op Oncol 2001; 13(6): 522-7.
179. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30(32): 3924-31.
180. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, Phase 3 study. Lancet 2012; 379(9825): 1508-16.
181. Kunz, A., Moran, J.K., Rubino, J., Jain, N., Boghaert, E.R., Hamann, P.R., Ruppen, M.E., Damle, N., Vidunas, E. Calicheamicin conjugates. US2006002942 (2006).
182. Tu X, LaVallee T, Lechleider R. CD22 as a target for cancer therapy. J Exp Ther Oncol 2011; 9(3): 241-8.
183. Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized Phase III trial. J Hepatol 2009; 51(6): 1030-6.
184. Beerman TA, Gawron LS, Shin S, Shen B, McHugh MM. C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells. Cancer Res 2009; 69(2): 593-8.
185. Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: Chemistry, biology and pharmacology. Anticancer Agents Med Chem 2008; 8(2): 123-31.
186. Zhang Q, Liu X, Xu S, Li C, Zhang Y, Yang J, et al. Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer. Cancer Biother Radiopharm 2012; 27(6): 384-91.
187. Ru Q, Shang BY, Miao QF, Li L, Wu SY, Gao RJ, et al. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity. Eur J Pharm Sci 2012; 47(4): 781-9.
188. Feng Y, He HW, Li BW, Zhang ZX, Chen X, Li XF. Inhibitory effects of the immunoconjugate composed of anti-type IV collagenase antibody Fab' fragment and lidamycin on tumor invasion and metastasis. Yao Xue Xue Bao 2011; 46(12): 1462-5.
189. Miao QF, Liu XY, Shang BY, Ouyang ZG, Zhen YS. An enediyneenergized single-domain antibody-containing fusion protein shows potent antitumor activity. Anticancer Drugs 2007; 18(2): 127-37.
190. Fang H, Miao QF, Zhang SH, Cheng X, Xiong DS, Zhen YS. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin. Sci China Life Sci 2011; 54(3): 255-62.
191. McGovren JP, Clarke GL, Pratt EA, DeKoning TF. Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot (Tokyo) 1984; 37(1): 63-70.
192. Ichimura M, Ogawa T, Katsumata S, Takahashi KI, Takahashi I, Nakano H. Duocarmycins, new antitumor antibiotics produced by streptomyces; Producing organisms and improved production. J Antibiot (Tokyo) 1991; 44(10): 1045-53.
193. Denny, W.A., Wilson, W.R., Stevenson, R.J., Tercel, M., Atwell, G.J., Yang, S., Patterson, A.V., Pruijn, F.B. Nitrobenzindoles and their use in cancer therapy. WO2006043839 (2006).
194. Boger, D.L. CBI analogues of the duocarmycins and CC-1065. WO2004101767 (2004).
195. Ghosh N, Sheldrake HM, Searcey M, Pors K. Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products. Curr Top Med Chem 2009; 9(16): 1494-524.
196. MacMillan KS, Boger DL. Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065. J Med Chem 2009; 52(19): 5771-80.
197. Boger DL, McKie JA. An efficient synthesis of 1,2,9,9atetrahydrocyclopropa[ c]benz[e]indol-4-one (CBI): An enhanced and simplified analog of the CC-1065 and duocarmycin alkylation subunits. J Org Chem 1995; 60(5): 1271-5.
198. Wang Y, Jiang J, Jiang X, Cai S, Han H, Li L, et al. Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC- 1065 analog. Bioorg Med Chem 2008; 16(13): 6552-9.
199. Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG, Denny WA, et al. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J Med Chem 2005; 48(5): 1344-58.
200. Beusker, P.H., Coumans, R.G.E., Elgersma, R.C., Menge, W.M.P.B., Joosten, J.A.F., Spijker, H.J., De Groot, F.M.H. Novel conjugates of CC-1065 analogs and bifunctional linkers. WO2011133039 (2011).
201. Beusker, P.H., Spijker, H.J., Joosten, J.A.F., Huijbregts, T., De Groot, F.M.H. Substituted CC-1065 analogs and their conjugates. WO2009017394 (2009).
202. Gangwar, S., Zhang, Q. Methods and compounds for preparing CC-1065 analogs. WO2007051081 (2007).
203. Ng, H.P., McGee, D.P.C., Wu, G., Li, Z., Gangwar, S., Saunders, O.L., Martichonok, V., Astafieva, I., Moore, J., Yarranton, G.T., King, D.J., Boyd, S., Lobl, T.J. Cytotoxins, prodrugs, linkers and stabilizers useful therefor. WO02096910 (2002).
204. Chari RVJ, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM, et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 1995; 55(18): 4079-84.
205. Yongxin, R., Chari, R.V.J. CC-1065 analog synthesis. US6534660 (2003).
206. Zhao RY, Erickson HK, Leece BA, Reid EE, Goldmacher VS, Lambert JM, et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem 2012; 55(2): 766-82.
207. Boursalian TE, McEarchern JA, Law CL, Grewal IS. Targeting CD70 for human therapeutic use. Adv Exp Med Biol 2009; 647: 108-19.
208. Derwin DW, Passmore D, Zhang Q, Sufi B, Pan C, Rao C, Huber M, et al. Enzymology of the mechanism of action for MDX-1203 antibody drug conjugate. AACR 103rd Annual Meeting, Mar 31-Apr 4, 2012; Chicago, USA.
209. Arima K, Kosaka M, Tamura G, Imanaka H, Sakai H. Studies on tomaymycin, a new antibiotic. I. Isolation and properties of tomaymycin. J Antibiot (Tokyo) 1972; 25(8): 437-44.
210. Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 2011; 20(6): 733-44.
211. Gauzy, L., Bouchard, H., Commercon, A., Deng, Y., Chari, R.V.J. Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use. EP2019104 (2009).
212. Howard, P.W., Jeffrey, S., Burke, P., Senter, P. Targeted pyrrolobenzodiazapine conjugates. WO2011130613 (2011).
213. Sutherland MSK, Walter RB, Jeffrey SC, Burke, PJ, Yu C, Harrington KH, et al. SGN-CD33A: A novel CD33-directed antibodydrug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against multi-drug resistant human AML.54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA, USA.
214. Pettit GR. The dolastatins. Fortschr Chem Org Naturst 1997; 70: 1-79.
215. Mohammad RM, Varterasian ML, Almatchy VP Hannoudi GN.,Pettit GR., Al-Katib A. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin Cancer Res 1998; 4(5): 1337-43.
216. Turner T, Jackson WH, Pettit GR, Wells A, Kraft AS. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate 1998; 34(3): 175-81.
217. Krug LM, Miller VA, Kalemkerian GP, Kraut MJ, Ng KK, Heelan RT, et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol 2000; 11(2): 227-8.
218. Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, et al. Phase II study of dolastatin-10 in patients with hormonerefractory metastatic prostate adenocarcinoma. Clin Cancer Res 2000; 6(11): 4205-8.
219. Shnyder SD, Cooper PA, Millington NJ, Pettit GR, Bibby MC. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int J Oncol 2007; 31(2): 353-60.
220. Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E, et al. Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des 1998; 13(4): 243-77.
221. Francisco, J.A., Risdon, G., Wahl, A.F., Siegall, C., Senter, P.D., Svetlana, D., Toki, B.E. Recombinant anti-CD30 antibodies and uses thereof. US20070258987 (2007).
222. Otani M, Natsume T, Watanabe J, Kobayashi M, Murakoshi M, Mikami T, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000; 91(8): 837-44.
223. Gualberto A. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs 2012; 21(2): 205-16.
224. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30(7): 631-7.
225. Deng C, Pan B, O'Connor OA. Brentuximab Vedotin. Clin Cancer Res 2013; 19(1): 22-7.
226. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26(8): 925-32.
227. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009; 114(13): 2721-9.
228. Chen, Y., Dennis, M., Dornan, D., Elkins, K., Junutula, J.R., Polson, A., Zheng, B. Anti-CD79B antibodies and immunoconjugates and methods of use. WO2009012268 (2009).
229. Cabezudo E, Carrara P, Morilla R, Matutes E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 1999; 84(5): 413-8.
230. Junutula, J., Mallet, W. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates. WO2008141044 (2008).
231. Keir CH, Vahdat LT. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther 2012; 12(2): 259-63.
232. Morris MJ, Yang BJ, Reyno LM, Anand B, Hartford A, Jelaca- Maxwell K, et al. Phase I trial of ASG-5ME in metastatic castration- resistant prostate cancer (CRPC). American Society of Clinical Oncology Annual Meeting; June 1-5, Chicago, USA (2012)
233. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009; 69(16): 6694-703.
234. Veiby P, Zhang J, Yang J, McDonald A, Fasanmade A, Wyant T, et al. The Investigational Drug MLN0264 First-in-human, First in Class ADC Targeting GCC: Phase I Dose-escalation Study and Supportive Scientific Rationale. 24th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'; November 6-9; Dublin 2012; 329.
235. Park, P.U., Bartle, L., Skaletskaya, A., Golmakher, V., Tavares, D., Deckert, J., Milol, V., Blanc, V. Novel anti-CD38 antibodies for the treatment of cancer. US20110262454 (2011).
236. Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10(2): 118-25.
237. Challita-Eid PM, Morrison K, Etessami S, An ZL, Morrison KJ, Perez-Villar JJ, et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007; 67(12): 5798-805.
238. Dennis, M., Rubinfeld, B., Polakis, P., Jakobovits, A. Antibodies and immunoconjugates and uses therefor. EP2502938 (2012).
239. Satpayev, D., Morrison, R.K., Morrison, K.J.M., Gudas, J., Jakobovits, A., Torgov, M., An, Z. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins. US20120078028 (2012).
240. Gudas JM, Torgov M, An Z, Jia XCJ, Morrison K, Morrison RK, et al. Ed. Use of AGS-16M8F as a novel antibody drug conjugate (ADC) for treating renal cancers. American Society of Clinical Oncology Annual Meeting June 3-7, Chicago, USA (2010).
241. Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, et al. Targeting pancreatic and ovarian carcinomas using the auristatin- based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer 2010; 103(5): 676-84.
242. Petrul HM, Schatz CA, Kopitz CC, Adnane L, McCabe TJ, Trail P, et al. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther 2012; 11(2): 340-9.
243. Kupchan SM, Komoda Y, Court WA, Thomas GJ, Smith RM, Karim A, et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972; 94(4): 1354-6.
244. Kupchan SM, Komoda Y, Branfman AR, Sneden AT, Court WA, Thomas GJ, et al. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J Org Chem 1977; 42(14): 2349-57.
245. Chari, R.V.I., Widdison, W.C. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents. WO02098883 (2002).
246. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992; 52(1): 127-31.
247. Burris HA, Tibbitts J, Holden SN, Sliwkowski MX, Phillips GDL. Trastuzumab emtansine (T-DM1): A novel agent for targeting HER2(+) breast cancer. Clin Breast Cancer 2011; 11(5): 275-82.
248. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21(2): 309-18.
249. Blackwell KL, Miles G, Gianni L, Krop IE, Weslau M, Baselga J, et al. Ed. Primary results from EMILIA, a Phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. American Society of Clinical Oncology Annual Meeting; June 1-5, Chicago, USA (2012)
250. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367(19): 1783-91.
251. Whiteman, K.R., O'Leary, J.J., Lutz, R.J. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer. WO2012138537 (2012).
252. Ricart AD. Immunoconjugates against solid tumors: Mind the gap. Clin Pharmacol Ther 2011; 89(4): 513-23.
253. Deckert J, Chicklas S, Yi Y, Li M, Pinkas J, Chittenden T, et al. Potent B-cell depletion by IMGN529, a CD37-targeting antibodymaytansinoid conjugate for the treatment of B-cell malignancies. Blood 2011; 118(21): 1591-2.
254. Deckert, J., Park, P., Tavares, D., Rui, L. CD37-binding molecules and immunoconjugates thereof. WO2011112978 (2011).
255. Gan HK, Burgess AW, Clayton AHA, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 2012; 72(12): 2924-30.
256. Weber R, Feng X, Foord O, Green L, Gudas J, Keyt B, Liu, Y., Rathanaswami, P., Raya, R., Yang, X.D., Corvalan, J., Foltz, I., Jia, X.-C., Kang, J., King, C.T., Klakamp, S.L., Qiaojuan, J.S. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof. WO2005012479 (2005).
257. Hamblett KJ, Kozlosky CJ, Liu H, Siu S, Arora T, Retter MW, et al. AMG595, a novel antibody drug conjugate approach for targeting EGFRvIII- expressing glioblastoma. Neuro Oncol 2011; 13: 115.
258. Ab, O., Tavares, D., Rui, L., Payne, G., Goldmakher, V.S. Folate receptor 1 antibodies and immunoconjugates and uses thereof. WO2011106528 (2011).
259. Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation. J Thorac Oncol 2012; 7(5): 833-40.
260. Qin, A., O'Leary, J.J., Schindler, J.E.S. Anti-integrin immunoconjugate dosing regimens. WO2011162933 (2011).
261. Chen, Q., Trikha, M., Lutz, R.J., Steeves, R.M., Amphlett, G. Antiintegrin immunoconjugates, methods and uses. WO2006062779 (2006).
262. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33(7): 405-12.
263. Tuszynski JA. SAR-3419. Antibody-drug immunoconjugate, Oncolytic. Drugs Fut 2012; 37(6): 419-22.
264. Morariu, R. Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms. WO2012156455 (2012).
265. Sanicola-Nadel, M., Williams, K., Schiffer, S.G., Rayhorn, P. Cripto blocking antibodies and uses thereof. US20120195912 (2012).
266. Kelly RK, Olson DL, Sun YP, Wen DY, Wortham KA, Antognetti G, et al. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer 2011; 47(11): 1736-46.
267. Kahnert, A., Light, D., Schneider, D., Parry, R., Satozawa, N., Heitner, T., Steidl, S., Schubert, U. Anti-mesothelin antibodies and uses therefor. WO2009068204 (2009).
268. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 2012; 11(3): 517-25.
269. Chari, R.V.J. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents. WO01024763 (2001).
270. Fishkin, N. Novel maytansinoid derivatives with sulfoxide linker. WO2012145112 (2012).
271. Lutz, R.J., Chari, R.V.J. Methods for decreasing ocular toxicity of antibody drug conjugates. US20120282282 (2012).
272. Govindan, S., Goldenberg, D.M. Camptothecin conjugates of anti- CD22 antibodies for treatment of B cell diseases. US20110305631 (2011).
273. Chang, C.-H., Goldenberg, D.M., Rossi, E.A. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases. WO2012024223 (2012).
274. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, et al. CD74: A new candidate target for the immunotherapy of Bcell neoplasms. Clin Cancer Res 2007; 13(18 Pt 2): 5556s-63s.
275. Cubas R, Li M, Chen C, Yao Q. Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009; 1796(2): 309-14.
276. Leung, S., Losman, M., Hansen, H. Humanization of an anticarcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications. US2008069775 (2008).
277. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009; 15(19): 6052-61.
278. Govindan, S.V. Immunoconjugates with an intracellularlycleavable linkage. US20120328634 (2012).
279. Qi, Y., Ma, S. The medicinal potential of promising marine macrolides with anticancer activity. ChemMedChem 2011; 6(3): 399-409.
280. Essack M, Bajic VB, Archer JAC. Recently confirmed apoptosisinducing lead compounds isolated from marine sponge of potential relevance in cancer treatment. Mar Drugs 2011; 9(9): 1580-606.
281. Pan L, Chai H, Kinghorn AD. The continuing search for antitumor agents from higher plants. Phytochem Lett 2010; 3(1): 1-8.
282. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: A new molecular perspective. Med Res Rev 2011; 31(3): 443-81.
283. Arpicco S, Dosio F, Stella B, Cattel L. Anticancer prodrugs: An overview of major strategies and recent developments. Curr Top Med Chem 2011; 11(18): 2346-81.
284. Smith CD, Zhang X, Mooberry SL, Patterson GML, Moore RE. Cryptophycin: A new antimicrotubule agent active against drugresistant cells. Cancer Res 1994; 54(14): 3779-84.
285. Bouchard, H., Brun, M.-P., Commercon, A., Zhang, J. Novel conjugates, preparation thereof, and therapeutic use thereof. US20120225089 (2012).
286. Joshi, H., Vangapandu, S., Aneja, R. Conjugates of noscapine and folic acid and their use in treating cancer. WO2010083104 (2010).
287. Rath S, Liebl J, Forst R, Ullrich A, Burkhart JL, Kazmaier U, et al. Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives. Br J Pharmacol 2012; 167(5): 1048-61.
288. Pando O, Stark S, Denkert A, Porzel A, Preusentanz R, Wessjohann LA. The multiple multicomponent approach to natural product mimics: Tubugis, N-substituted anticancer peptides with picomolar activity. J Am Chem Soc 2011; 133(20): 7692-5.
289. Floyd WC, Datta GK, Imamura S, Kieler-Ferguson HM, Jerger K, Patterson AW, et al. Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in C26 tumor bearing mice. ChemMedchem 2011; 6(1): 49-53.
290. Schluep T, Gunawan P, Ling M, Jensen GS, Duringer J, Hinton S, et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 2009; 15(1): 181-9.
291. Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, et al. In vivo structural activity and optimization studies of folatetubulysin conjugates. Mol Pharm 2009; 6(5): 1518-25.
292. Dumontet C, Jordan MA. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9(10): 790-803.
293. Cai X, Gray Jr PJ, Von Hoff DD. DNA minor groove binders: Back in the groove. Cancer Treat Rev 2009; 35(5): 437-50.
294. Hamilton PL, Arya DP. Natural product DNA major groove binders. Nat Prod Rep 2012; 29(2): 134-43.
295. Wieland T, Faulstich H. Amatoxins, phallotoxins, phallolysin, and antamanide: The biologically active components of poisonous Amanita mushrooms. CRC Crit Rev Biochem 1978; 5(3): 185-260.
296. Simon, W., Lutz, C., Anderl, J., Mueller, C. Amatoxin-conjugates with improved linkages. WO2012119787 (2012).
297. Anderl, J., Simon, W., Mueller, C. Amatoxin-conjugates with improved linkers. WO2012041504 (2012).
298. Moldenhauer G, Salnikov AV, Luttgau S, Herr I, Anderl J, Faulstich H. Therapeutic potential of amanitin-conjugated antiepithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 2012; 104(8): 622-34.
299. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14(3): 154-69.
300. Guidi, C.J., Zhou, H.X., Zhang, C., Tavares, D., Park, P. Antiendoglin (CD105) antibodies, immunoconjugates, and uses thereof. WO2012149412 (2012).
301. Gerber, H.-P., Dijoseph, J.F., Khandke, K.M., Marquette, K.A., Sapra, P., Tchistiakova, L.G. Antibody-drug conjugates. WO2012131527 (2012).
302. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64: 15-29.
303. Daugherty, P., Stagliano, N.E., Jerry, T.W., Kamath, K., West, J., Khare, S. Activatable binding polypeptides and methods of indentifcation and use thereof. GB2455449 (2009).
304. Stagliano, N.E., West, J.W., Kamath, K., Bessette, P.H., Gluck, F., Sagert, J., Daugherty, P. Variable frequency drive system apparatus and method for reduced ground leakage current and transistor protection. AU20110203353 (2011).
305. Stagliano, N.E., West, J.W., Kamath, K., Bessette, P.H., Gluck, F., Sagert, J. Proproteins and methods of use thereof. AU2010215761 (2011) & US20130101555 (2013).
306. Xu D, McKee CM, Cao Y, Ding Y, Kessler BM, Muschel RJ. Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease Nexin-1. Cancer Res 2010; 70(17): 6988-98.
307. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013; 81(1):113-21.
308. Chen J, Yin S, Wu Y, Ouyang J. Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates. Anal Chem 2013; 85(3): 1699-704.
309. Lyon RP, Meyer DL, Setter JR, Senter PD. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol 2012; 502: 123-38.
310. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010; 16(19): 4769-78.
311. Chennamsetty, N., Helk, B., Kayser, V., Trout, B., Voynov, V. Methods for identification of sites for IgG conjugation. WO2010141902 (2010).
312. Voynov V, Chennamsetty N, Kayser V, Wallny HJ, Helk B, Trout BL. Design and application of antibody cysteine variants. Bioconj Chem 2010; 21(2): 385-92.
313. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30(2): 184-9.
314. Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, et al. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: Case study of TENB2. Br J Pharmacol 2013; 168 (2):445-57.
315. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 2009; 106(29): 11937-42.
316. Hofer T, Thomas JD, Burke Jr TR, Rader C. An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci USA 2008; 105(34): 12451-6.
317. Cho, H., Daniel, T., Hays, A.-M., Wilson, T., Litzinger, D., Mariani, R., Kimmel, B., Keefe, W. Biosynthetic polypeptides utilizing non-naturally encoded amino acids. US2010048871 (2010).
318. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA 2012; 109(40): 16101-6.
319. Strop, P., Dorywalska, M.G., Rajpal, A., Shelton, D., Liu, S.-H., Pons, J., Dushin, R. Engineered polypeptide conjugates and methods for making thereof using transglutaminase. WO2012059882 (2012) & US20130230543 (2013).
320. Widdison, W.C. Novel maytansinoid derivatives with peptide linker and conjugates thereof. WO2012177837 (2012) & US20130029900A1 (2013).
321. Ducry, L., Stump, B., Wong, H., She, J., Phillips, G. Branched linker for protein drug conjugates. WO2012113847 (2012).
322. Flygare, J.A., Junutula, J.R., Pillow, T.H. Alaninyl maytansinol antibody conjugates. US20120121615 (2012).
323. Jin, S. Process for manufacturing conjugates of improved homogeneity. WO2012135522 (2012).
324. Li, X., Worful, J. Preparation of maytansinoid antibody conjugates by a one-step process. WO2012135517 (2012) & WO2013135517A3 (2013).
325. Prudent, J. Extracellular targeted drug conjugates. WO2012122514 (2012).
326. Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29th March 1, 2012, Frankfurt, Germany. mAbs 2012; 4(6): 637-47.
327. Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: The other side of antibodies. J Hematol Oncol 2012; 5: 16.
328. Gupta M, Agrawal GP, Vyas SP. Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting. Curr Mol Med 2013; 13(1): 179-204.
329. Paszko E, Senge MO. Immunoliposomes. Curr Med Chem 2012; 19(31): 5239-77.
330. Janthur WD, Cantoni N, Mamot C. Drug conjugates such as antibody drug conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci 2012; 13(12): 16785-95.